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Objectives: Therapeutic hypothermia (TH) has been shown to improve survival and neurological 
outcome in patients resuscitated after out of hospital cardiac arrest (OHCA) from ventricular 
fibrillation/ventricular tachycardia (VF/VT). We evaluated the effects of using a TH protocol in a 
large community hospital emergency department (ED) for all patients with neurological impairment 
after resuscitated OHCA regardless of presenting rhythm. We hypothesized improved mortality and 
neurological outcomes without increased complication rates.
Methods: Our TH protocol entails cooling to 33°C for 24 hours with an endovascular catheter.  
We studied patients treated with this protocol from November 2006 to November 2008. All non-
pregnant, unresponsive adult patients resuscitated from any initial rhythm were included. Exclusion 
criteria were initial hypotension or temperature less than 30°C, trauma, primary intracranial event, 
and coagulopathy. Control patients treated during the 12 months before the institution of our TH 
protocol met the same inclusion and exclusion criteria. We recorded survival to hospital discharge, 
neurological status at discharge, and rates of bleeding, sepsis, pneumonia, renal failure, and 
dysrhythmias in the first 72 hours of treatment. 
Results: Mortality rates were 71.1% (95% CI, 56-86%) for 38 patients treated with TH and 72.3% 
(95% CI 59-86%) for 47 controls. In the TH group, 8% of patients (95% CI, 0-17%) had a good 
neurological outcome on discharge, compared to 0 (95% CI 0-8%) in the control group. In 17 
patients with VF/VT treated with TH, mortality was 47% (95% CI 21-74%) and 18% (95% CI 0-38%) 
had good neurological outcome; in 9 control patients with VF/VT, mortality was 67% (95% CI 28-
100%), and 0% (95% CI 0-30%) had good neurological outcome. The groups were well-matched 
with respect to sex and age. Complication rates were similar or favored the TH group.
Conclusion:	Instituting a TH protocol for OHCA patients with any presenting rhythm appears safe 
in a community hospital ED. A trend towards improved neurological outcome in TH patients was 
seen, but did not reach significance. Patients with VF appeared to derive more benefit from TH than 
patients with other rhythms. [West J Emerg Med. 2010; 11(4):367-372.]
INTRODUCTION
In the United States, the incidence of out-of-hospital 
cardiac arrest (OHCA) is increasing, with approximately 
166,200 patients suffering OHCA annually.1 Survival among 
resuscitated patients remains low, and the majority of 
survivors have a poor neurological outcome. 2,3 Recently, 
aggressive post-resuscitation care has been recognized as an 
important link in the cardiac arrest chain of survival. 
Therapeutic hypothermia (TH) was used to treat patients 
resuscitated from cardiac arrest during the 1950s;4 however, 
complications related to the depth of cooling led to this 
treatment being abandoned. Positive outcomes from animal 
studies in the 1990s, rekindled interest in this treatment 
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and reperfusion injury by decreasing cerebral metabolism, 
suppressing the release of oxygen free radicals and excitatory 
neurotransmitters, and by decreasing the inflammatory 
response. 6,7 In 2002, two randomized controlled trials 
evaluated the effect of mild TH on comatose patients 
resuscitated after ventricular fibrillation OHCA and 
demonstrated improvements in survival and neurological 
outcome. 8, 9 Currently, both the International Liaison 
Committee on Resuscitation (ILCOR) and the American Heart 
Association (AHA) recommend the use of TH in the treatment 
of persistently comatose patients resuscitated after ventricular 
fibrillation OHCA. 10, 11
A number of studies published since 2002 support the use 
of TH after cardiac arrest, but only one was conducted solely 
at a community hospital.12-18 Also, few data have been 
published on patients treated with TH after presenting with 
rhythms other than non-perfusing ventricular fibrillation or 
ventricular tachycardia (VF/VT); consequently, firm 
conclusions cannot be drawn about the benefits of TH in these 
other populations.9, 19-22
In November 2006, we began to treat comatose patients 
resuscitated from OHCA with TH, regardless of their 
presenting rhythm. We hypothesized that establishing this 
protocol in our community hospital emergency department 
(ED) would decrease mortality and improve neurological 
outcome in these patients without increasing complication 
rates. The primary aim of our study was to assess the impact 
of our TH protocol on in-hospital mortality by comparing the 
mortality rates of treated patients with those of control patients 
from the preceding 12 months. Secondarily, we evaluated the 
neurological status upon hospital discharge and complication 
rates of both groups. 
METHODS
Study Design
We conducted a retrospective, observational study of the 
mortality of patients resuscitated from OHCA in our ED from 
November 2006 through November 2008. The control group 
consisted of patients treated in our ED during the preceding 12 
months, prior to the implementation of our TH protocol. This 
study was approved by the hospital’s Institutional Review 
Board, with a waiver of informed consent.
Study Setting and Population 
This study was conducted at a large tertiary care suburban 
community hospital with over 85,000 ED visits annually and 
nearly 700 inpatient beds. 
Study Protocol
For our TH protocol we use an endovascular cooling 
catheter (ICY Catheter, IC-3893, Alsius, Irvine CA) with the 
goal to cool the patient to a target temperature of 33 °C within 
four hours. The Alsius ICY catheter is only intended for 
placement in the femoral vein. No patients were given cold 
intravenous saline. Our protocol advises using ice packs if the 
target temperature is not reached in four hours, but their use 
was not routinely noted in the medical record. Temperatures 
are monitored with a rectal or esophageal temperature probe. 
Patients are cooled for 24 hours from the onset of cooling, and 
then actively re-warmed at a rate of 0.5 °C/hour to a goal 
temperature of 36.5 °C using the endovascular catheter. 
Shivering is prevented with sedative medications, such as 
propofol, lorazepam and fentanyl; paralytics are added only if 
sedatives are ineffective. Vital signs are measured every 30 
minutes until the goal temperature is reached and then every 
two hours. At the onset of cooling and at eight and 16 hours, 
blood tests and a 12-lead ECG is performed. The blood tests 
include a complete blood count, metabolic panels, coagulation 
studies, cardiac enzymes and arterial blood gas. Additionally, 
two sets of blood cultures are obtained at eight hours. Other 
testing and treatments are at the discretion of the treating 
physicians. Patients treated with TH are eligible for 
percutaneous coronary intervention (PCI) and anti-
coagulation. Decisions regarding withdrawal of care are made 
by the primary physician or intensivist, usually in consult with 
a neurologist, but do not follow a standardized protocol. Study 
investigators are not involved in end-of-life decisions.
Patients were eligible for treatment with TH if they were 
18 years of age or older and remained unresponsive to verbal 
stimuli following return of spontaneous circulation (ROSC) 
after cardiac arrest. Patients with any initial rhythm and with 
witnessed or unwitnessed arrest were eligible. Exclusion 
criteria were pregnancy, a systolic blood pressure less than 
90mmHg despite the use of vasopressors, traumatic injuries, 
an initial temperature less than 30°C, a primary intracranial 
event determined by physician judgment, and known pre-
existing coagulopathy. Eligible patients were treated with TH 
at the discretion of the treating physician. 
We identified patients primarily by searching records from 
our ED automated medication and supply management 
machine for documentation that an endovascular cooling 
catheter had been dispensed. To ensure that we located all 
eligible patients, we also searched the diagnosis field of our 
ED’s electronic medical record (EMR) using the key words: 
arrest, vfib, vtach, fibrillation, ventricular, asystole, and PEA 
(pulseless electrical activity). 
We identified patients in our control group by searching 
our EMR diagnosis field for the same keywords. The charts 
extracted were reviewed to determine if the patients treated 
before the institution of our TH protocol met the same 
inclusion and exclusion criteria as our study group and 
survived to hospital admission. 
Measurements
We created a standardized abstraction form for data 
collection prior to the start of the study. The data collected 
included patient demographics, hospital length of stay (LOS), 
survival to hospital discharge, initial recorded arrest rhythm, 
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and neurological status at discharge using the Glasgow-
Pittsburgh Cerebral Performance Category (CPC). We 
determined the CPC by chart review. Abstractors were not 
blinded to the patient’s treatment group if it was specified in 
the inpatient chart. We also recorded complications during the 
first 72 hours, using pre-determined definitions. These 
included the rate of significant bleeding (requiring transfusion, 
or surgical or gastroenterological consultation), sepsis 
(meeting systemic inflammatory response syndrome criteria 
plus documented infection or positive culture), pneumonia 
(infiltrate on chest radiograph or clinical diagnosis recorded 
on chart), renal failure (new use of dialysis or continuous renal 
replacement therapy), and arrhythmias (requiring medical or 
electrical therapy) in the first 72 hours.
Chart abstractors met at the start of the study to define 
methods and were unaware of patient outcomes when 
abstracting data from ED records. 
Our primary outcome was in-hospital mortality. Our 
secondary outcomes were neurological status on hospital 
discharge and complication rates. 
Data Analysis
For the study group, our analysis of outcomes includes 
all patients for whom we initiated our TH protocol, regardless 
of whether the target temperature was reached, cooling was 
halted, or the patient died before hospital admission. We did 
not include patients who had ROSC during the study period 
but did not have TH initiated, even if they met inclusion and 
exclusion criteria. Demographic and clinical characteristics 
are described by means with 95% confidence intervals (CI) for 
normally distributed data and by medians with interquartile 
range (IQR) for non-normal data. We compared the mortality 
of each of the two groups with 95% CI, and compared the 
unadjusted mortality between the two cohorts with the χ2 test. 
We considered values of p < 0.05 to be statistically significant. 
Analyses were performed using SPSS version 15.0 (SPSS 
Inc., Chicago, IL).
RESULTS 
Seventy-two patients with ROSC survived to hospital 
admission during our study period. Of these, 34 were eligible 
for TH but were not cooled for the following reasons: catheter 
could not be placed (n=7), co-existing infection (n=4), poor 
baseline health (n=4), deemed too unstable (n=3), do-not-
resuscitate status (n=2), cooling unit in use for another patient 
(n=1), various (n=6) or unrecorded reasons (n=6). Reasons for 
catheter placement failure included the large size of the 
catheter, thrombus in the vein, contractures, skin breakdown 
and body habitus. Of the six patients with various reasons 
recorded, two had respiratory arrest followed by cardiac arrest, 
which likely was interpreted as a contraindication for TH; one 
had pulmonary embolism; one had suspected aortic dissection; 
one was transported for emergent PCI before the TH catheter 
was placed; and one patient was not treated due to “unknown 
baseline mental status.” 
The remaining 38 patients were treated with our TH 
protocol. We were unable to determine time-to-target 
temperature in 13 patients (34.2%), either because the 
patient’s temperature was not recorded after the cooling 
catheter was placed or because the time of initiation of TH 
was not clearly documented. In the remaining 25 patients the 
median time to reach the target temperature was 240 minutes 
(IQR 115 min to 405 min).
Table	1. Summary of complications in the TH-treated patients.
Therapeutic	hypothermia Control
% (n) or median 95% CI or IQR % (n) or median 95% CI or IQR
Mortality 71.1% (27)  56% to 86% 72.3% (34)  59% to 86%
CPC 1 - 2 at discharge 8% (3) 0% to 17% 0 (0) 0% to 8%
Length of stay (days) 4.5  2 to 11.5  2  1 to 8
Mortality, VF/VT subgroup 47% (8) 21% to 74% 67% (6) 28% to 100%
CPC 1 - 2 at discharge, VF/VT subgroup 18% ( 3) 0% to 38% 0 (0) 0% to 30%
Complications
Bleeding 16% (6)  4% to 28% 32% (15) 18% to 46%
Pneumonia 21% (8) 7% to 35% 26% (12) 13% to 38%
Sepsis 24% (9) 10% to 38% 40% (19) 26% to 55%
Renal failure 5% (2) 0% to 13% 6% (3)  0% to 14%
Pulmonary edema 24% (9)  10% to 38% 19% (9)  7% to 31%
Seizures 13% (5) 2% to 24% 17% (8)  6% to 28%
Arrhythmias 18% (7) 6% to 31% 49% (23)  34% to 64%
CPC, Cerebral Performance Category; VF/VT, ventricular fibrillation/ventricular tachycardia; CI, confidence interval; IQR, interquartile 
range
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For patients treated with TH, the mortality rate was 71.1% 
(95% CI 56% to 86%) with an odds ratio of 0.94 (95% CI 0.36 
to 2.42). Eight percent (95% CI 0% to 17%) had a good 
neurological outcome (defined as a Glasgow-Pittsburgh CPC 
score of 1 or 2) on hospital discharge. The initial documented 
rhythms in this group were VF/VT in 44.7% (n=17), PEA in 
31.6% (n=12), and asystole in 23.7% (n=9). The arrest was 
witnessed in 20 patients (52.6%). The median age was 74.5 
(IQR 60 – 81) years; the median hospital LOS was 4.5 (IQR 2 
– 11.5) days; and 55% were male (Tables 1 and 2). Five 
patients (13.2%) did not complete the protocol. 
Complications in the TH-treated patients were as follows: 
bleeding in six [16% (95% CI 4% to 28%)]; pneumonia in 
eight [21% (95% CI 7% to 35%)]; sepsis in nine [24% (95% 
CI 10% to 38%)]; renal failure in two [5% (95% CI 0% to 
13%)];arrhythmias in seven [18% (95% CI 6% to 31%)]; and 
seizures in five [13% (95% CI 2% to 24%)] (Table 1).
Our control group included 47 patients, with a mortality 
rate of 72.3% (95% CI 59% to 86%). None (95% CI 0% to 
8%) had a good neurological outcome on hospital discharge. 
The presenting rhythms of the control group were VF/VT in 
19.2% (n=9), PEA in 36.2% (n=17), asystole in 42.6% (n=20), 
and 2.1% documented as slow wide complex (n=1). Cardiac 
arrest was witnessed in 25 (53.2%) patients. The median age 
was 75 (IQR 60 to 83) years, the median hospital LOS was 
two (IQR 1 to 8) days, and 57% were male (Tables 1 and 2).
Complications in the control group were as follows: 
bleeding in 15 [32% (95% CI 18% to 46%)]; pneumonia in 12 
[26% (95% CI 13% to 38%)]; sepsis in 19 [40% (95% CI 26% 
to 55%)]; renal failure in three [6% (95% CI 0% to 14%)]; 
arrhythmias in 23 [49% (95% CI 34% to 64%)]; and seizures 
in eight [17% (95% CI 6% to 28%)] (Table 1).
Of the 17 patients treated with TH whose initial 
documented rhythm was VF/VT, mortality was 47% (95% CI 
21% to 74%). We observed good neurological outcome in 
18% of these patients (95% CI 0% to 38%). Of the nine in the 
control group with an initial documented rhythm of VF/VT, 
mortality was 67% (95% CI 28% to 100%). Good 
neurological outcome was seen in none of these patients (95% 
CI 0% to 30%) (Table 1).
The mortality rate for all 72 patients who had ROSC and 
survived to hospital admission during the study period was 
70.8% (95% CI 59% to 80%). The 34 patients who met the 
inclusion and exclusion criteria for TH but were not treated 
had a mortality rate of 70.6% (95% CI 17% to 46%). Four of 
these 34 patients who were eligible but not treated with TH 
had an initial documented rhythm of VF/VT. 
DISCUSSION
The mortality rate of patients treated with our TH protocol 
was not significantly different from that of our control 
patients; however, we did find a non-statistically significant 
trend towards improved neurological outcomes in the TH 
group. Complication rates were also not significantly different 
between the two groups, although there was a trend towards 
more bleeding, sepsis and arrhythmias in the control group. In 
Table	2. Baseline characteristics of patients.
Control
%	(n)	or	median	(IQR)
Therapeutic	hypothermia
%	(n)	or	median	(IQR) P	value
Gender (male) 57% (27)  55% (21)  0.840
Age (years) 75 (60 - 83) 74.5 (60 – 81)  0.521
Diabetes mellitus 42.6 % (20) 42.1% (16) 0.967
Hypertension 61.7 % (29) 63.2% (24) 0.890
Coronary artery disease 42.6% (20) 42.1% (16) 0.967
Prior CVA 14.9% (7) 13.2% (5) 0.819
Renal failure 8.5% (4) 15.8% (6) 0.300
Congestive heart failure 31.9% (15) 15.8% (6) 0.087
Cancer 19.1% (9) 5.3% (2) 0.058
On warfarin 21.3% (10) 13.2% (5) 0.329
Presenting	rhythm
VF/VT 19.2% (9) 44.7% (17) 0.008
Asystole 36.2% (17) 31.6% (12) 0.068
PEA  42.6% (20) 23.7% (9) 0.657
Other 2.1% (1) 0 0.366
Witnessed arrest 53.2% (25) 52.6% (20) 0.959
CVA, Cerebral Vascular Accident; VF/VT, ventricular fibrillation/ventricular tachycardia; PEA, pulseless electrical activity; IQR, 
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patients with an initial rhythm of VF/VT, there was a trend 
towards improved mortality and neurological outcomes in the 
group treated with TH. 
The number of published studies supporting the use of TH 
in the setting of resuscitated cardiac arrest continues to grow. 
12-15, 16, 17 A recent review of studies of patients treated with TH 
after ROSC from any presenting rhythm concluded that its use 
improved survival and favorable neurological outcome with 
an odds ratio of 2.5 for both measures; of note, only one of the 
included studies was performed at a community hospital.23 In 
other studies including all rhythms, much of the survival and 
neurological outcome benefit was limited to patients 
presenting with VF/VT cardiac arrest. 16, 17, 24 However, a 
recent study by Nielsen et al. reported a more dramatic effect 
of TH in non- VF/VT rhythms. Twenty-one percent of patients 
with an initial rhythm of asystole and 22% with PEA were 
discharged with good neurological outcome.25
Our overall survival rates and numbers of patients 
discharged with favourable outcomes were low compared to 
the landmark trials by Bernard and the HACA group.8, 9 Unlike 
those trials, we included patients with any presenting rhythm 
as well as patients with unwitnessed cardiac arrest. In 
addition, the median age of our patients was 10-15 years 
greater. 8, 9 All of these factors would be expected to lower 
survival rates. 
Some decrease in the rate of favourable outcomes is not 
uncommon when a therapy is initially studied in a community 
hospital setting. 24 The one other published study performed at 
a community hospital demonstrated a lower mortality rate 
(61%) and higher rate of discharge with good neurological 
outcome (33%).18 Their study population was younger (mean 
age of 62 compared to a median age of 75); they did not 
specify presenting rhythms and used a different neurological 
outcome scale. These factors limit the ability to compare the 
outcomes between studies. 
Although our study did not find a statistically significant 
benefit from TH, our sample size was small, increasing the 
likelihood of a type 2 error. The percentage of patients 
presenting with VF/VT was low in our study compared to 
others that included all rhythms, which may have depressed 
the expected treatment benefit.16, 17, 24 In patients with VF/VT, 
where the evidence of benefit from TH is stronger, our point 
estimates show an improvement in the incidence of good 
neurological outcome from 0 to 18%. If this effect was borne 
out with a larger sample size, the use of a TH protocol would 
be justified. The published evidence of benefit for rhythms 
other than VF/VT is not as robust, and none was found in our 
study. 
ILCOR and the AHA recommend the use of TH in 
unresponsive patients resuscitated after ventricular fibrillation 
OHCA. It is estimated that an additional 2,298 patients per 
year in the United States would have a good neurological 
outcome if TH was fully implemented in comatose survivors 
of OHCA. 26Despite this recommendation, TH continues to 
be underused. In a 2005 survey of emergency physicians, 
cardiologists and critical care specialists involved in post-
resuscitation care, 74% of United States respondents had 
never used TH.27 Commonly cited reasons for not using TH 
included “not enough data”, “not part of Advanced Cardiac 
Life Support Guidelines”, “have not considered cooling 
therapy”, and “too technically difficult to use.”27 In developing 
our TH protocol, we encountered these same barriers to 
implementation despite significant educational efforts for 
our physicians and nurses. In the present study, 14 of 34 
potentially eligible patients were not treated with TH for 
reasons that were not clearly documented, and seven of the 
34 were not cooled because placement of the endovascular 
catheter was unsuccessful.
LIMITATIONS
There are a number of limitations to our study, including 
its being limited to a single institution with a small sample 
size. We chose to evaluate in-hospital mortality and 
neurological outcome at the time of hospital discharge rather 
than longer-term survival and disability. We used the 
Glasgow-Pittsburgh CPC as our neurological outcome 
measure. The CPC has been criticized for being a relatively 
gross assessment tool;28  however, it still is a standard outcome 
measure used in resuscitation research. Our protocol and study 
design designated the use of an endovascular catheter for 
cooling, thus limiting our ability to generalize our results to 
institutions using alternative cooling techniques. The 2005 
AHA guidelines for emergency cardiovascular care were 
published before the period of our historical controls, and no 
other significant changes in ED resuscitation were 
implemented during our study. However, the medical and 
cardiac intensive care units (ICUs) at our hospital became 
closed units in June 2008, which may have impacted the care 
of TH patients in the ICU as compared with historical 
controls. Our hospital does not have a standardized protocol 
for comprehensive post-resuscitation care, although some 
protocols, including emergent PCI and maintenance of 
euglycemia, do exist.
Although our control and study groups did not differ 
statistically with regard to baseline characteristics, the control 
group did contain more patients with congestive heart failure 
and cancer. In addition, there were statistically fewer control 
patients who presented with VF/VT as opposed to other 
rhythms in comparison to the study population. Both factors 
likely favor the group treated with TH. 
CONCLUSION
Although we demonstrated a trend towards improved 
neurologic outcomes in patients treated with TH as compared 
with historical controls, we found no overall difference in 
mortality. In patients with an initial rhythm of VF/VT, those 
treated with TH showed a trend towards improved mortality 
and neurologic outcomes. Our TH protocol appears safe, 
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as we found no significant difference in complication rates 
between patients treated with TH and historical controls. 
Large collaborative descriptive studies of TH are now needed 
especially involving non-university institutions and patients 
with presenting rhythms other than VF/VT.
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